

11 November 2022

High Cost Drugs in Ophthalmology

Request

I am researching the usage of high cost drugs in Ophthalmology. Your answers to the following questions will be highly appreciated.

1 – For the 4 months from May to August 2022, how many patients received the following anti-VEGF treatments for any eye condition:

Aflibercept	3672
Bevacizumab	3
Brolucizumab	0
Dexamethasone	39
Faricimab	0
Ranibizumab – Lucentis	1454
Ranibizumab – Ongavia	0

2 – For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatment listed below, excluding patients who previously had any anti-VEGF therapy

Aflibercept	85
Bevacizumab	0
Brolucizumab	0
Dexamethasone	20
Faricimab	0
Ranibizumab – Lucentis	19
Ranibizumab – Ongavia	0